These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20975512)

  • 1. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
    Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
    AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.
    Tebas P; Tuluc F; Barrett JS; Wagner W; Kim D; Zhao H; Gonin R; Korelitz J; Douglas SD
    PLoS One; 2011; 6(9):e24180. PubMed ID: 21931661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.
    Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
    J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
    Tebas P; Spitsin S; Barrett JS; Tuluc F; Elci O; Korelitz JJ; Wagner W; Winters A; Kim D; Catalano R; Evans DL; Douglas SD
    AIDS; 2015 May; 29(8):931-9. PubMed ID: 25915168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
    Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD
    Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
    Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages.
    Wang X; Douglas SD; Song L; Wang YJ; Ho WZ
    J Neuroimmune Pharmacol; 2008 Dec; 3(4):257-64. PubMed ID: 18654860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
    Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
    Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
    Lelas S; Li YW; Wallace-Boone TL; Taber MT; Newton AE; Pieschl RL; Davis CD; Molski TF; Newberry KS; Parker MF; Gillman KW; Bronson JJ; Macor JE; Lodge NJ
    Neuropharmacology; 2013 Oct; 73():232-40. PubMed ID: 23770339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.
    Barrett JS; Bajaj G; McGuire J; Wu D; Spitsin S; Moorthy G; Zhao X; Tebas P; Evans DL; Douglas SD
    Curr HIV Res; 2014; 12(2):121-31. PubMed ID: 24862330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
    Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
    Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant--a novel NK1-receptor antagonist.
    Patel L; Lindley C
    Expert Opin Pharmacother; 2003 Dec; 4(12):2279-96. PubMed ID: 14640927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.
    Spitsin S; Tebas P; Barrett JS; Pappa V; Kim D; Taylor D; Evans DL; Douglas SD
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
    Van Laere K; De Hoon J; Bormans G; Koole M; Derdelinckx I; De Lepeleire I; Declercq R; Sanabria Bohorquez SM; Hamill T; Mozley PD; Tatosian D; Xie W; Liu Y; Liu F; Zappacosta P; Mahon C; Butterfield KL; Rosen LB; Murphy MG; Hargreaves RJ; Wagner JA; Shadle CR
    Clin Pharmacol Ther; 2012 Aug; 92(2):243-50. PubMed ID: 22739139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
    Prommer E
    J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.
    Schwartz L; Spitsin SV; Meshki J; Tuluc F; Douglas SD; Wolfe JH
    J Neurovirol; 2013 Jun; 19(3):219-27. PubMed ID: 23765222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P and the Neurokinin-1 Receptor: The New CRF.
    Schank JR; Heilig M
    Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors.
    Halik PK; Lipiński PFJ; Matalińska J; Koźmiński P; Misicka A; Gniazdowska E
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.